Liana, diagnosed with hATTR amyloidosis
and her daughter Gabriella (Brazil)
Our Company
OUR PATIENT ACCESS PHILOSOPHY
Our Commitment to Patients and Partners
At Alnylam, we all live by a shared philosophy when it comes to patient access: Our innovative therapies must get to those who may benefit from them. That philosophy of putting the patient first isn’t just a belief common among our leadership and employees, it’s a statement of intent and a specific set of actions that we’ve undertaken as a company. As part of our commitment, we publish an annual Patient Access Philosophy Report as a read-out on our progress.
Our Patient Access Philosophy was created well before our first medicine was even approved, because we wanted to ensure that in preparing to be a commercial-stage biopharmaceutical company, we had a North Star guiding how we behave and the decisions we make to ensure that patients around the world can access every medicine we develop. These principles guide our P5x25 strategy as we endeavor to become a top five biotech in the next five years.
At Alnylam, we know that medical and scientific innovation are only worth while if the people who can benefit from life-changing therapies have access to them. Despite living in an age of medicinal breakthroughs, patients are too often unable to receive the treatment they need due to their location, their insurance, or other obstacles. We are committed to working with partners around the world to ensure our drugs are accessible and affordable to all, because no patient should have to wait for hope. - Yvonne Greenstreet, MBChB, CEO of Alnylam
Alnylam’s Patient Access Philosophy Commitment
Help Patients
- Above all, we put patients first.
- We recognize that access means more than insurance coverage. We have broadened our definition of access to consider distribution and point-of-care.
- We are continuing our journey of building strong relationships with our patient communities. We partner with patient advocacy groups, healthcare providers, payers, and regulators to support disease awareness, diagnosis, and access efforts.
- We are diversifying and expanding patient access programs because there is no one-size-fits-all model for healthcare accessibility.
- We listen to the challenges of patients and partners and respond with meaningful, practical solutions.
- We take proactive steps for better access today to advance innovation that will enable us to help even more people in the future.
Deliver Value to Payers and Partners Globally
- We view patient access as a responsibility that requires innovation to remove barriers to access and respond to the concerns of payers.
- Whether evolving approaches to reimbursement or trailblazing new markets, we are breaking down barriers to access by delivering value to payers and regulators, making the concept of value-based care a reality.
- We demonstrate evidence-based value objectively and transparently.
- We establish responsible pricing that reflects value delivered to patients, caregivers, and society.
- We are expanding our geographic presence rapidly and working with local governments and industry leaders to ensure our treatments are accessible and affordable to all patients who need them.
- We remain committed to growth through continuous innovation, not arbitrary price increases.
Be Proactive and Accountable
- We recognize that no single solution can meet all payer challenges. Each drug and each patient population present unique challenges, colored by a myriad of factors. We advocate for policies that promote innovation, value communication, and fortify patient access.
- We’ve developed innovative reimbursement contracts, and we’ve then gone the next step to take these contracts from concept to operational feasibility.
- As we continue developing new drugs and overcoming barriers to access in this golden age of medicine, our core principles guide us. We always act with medical and scientific excellence and integrity.
- In the spirit of understanding and responding to those risks that matter most to payers, we continue to evolve new frameworks, acting with urgency to minimize the time it takes to get approved therapies to patients.
- We track and report our efforts to help patients access our therapies.
Our Patient Access Philosophy enables us to measure progress against three key factors:
-
Patients come first
-
Innovation is key in everything we do
-
Accountability is a must
Understand how by downloading our latest Patient Access Philosophy Report
Alnylam Assist® offers you a number of personalized services throughout your treatment with an Alnylam product.
YOU ARE NOW LEAVING ALNYLAM.COM
You are now being directed to another Alnylam website that contains information about specific treatment(s).
Alnylam Act® provides no-charge, independent genetic testing and counseling to individuals in the U.S. and Canada who may have hATTR amyloidosis, acute hepatic porphyria, or primary hyperoxaluria type 1.